Two trials bring new advances for patients with metastatic colorectal cancer: First-line data show longer disease control in MSI-H/dMMR and higher responses in BRAF V600E. Lawrence L. Cancer 2026;132:e70368.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lawrence L. Two trials bring new advances for patients with metastatic colorectal cancer: First-line data show longer disease control in MSI-H/dMMR and higher responses in BRAF V600E. Cancer 2026;132:e70368.
PMID: 42083467